Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Akebia Therapeutics (AKBA) Other Gross PP&E Adjustments (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Gross PP&E Adjustments for 10 consecutive years, with -$5.3 million as the latest value for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 45.6% to -$5.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.3 million through Dec 2025, up 45.6% year-over-year, with the annual reading at -$5.3 million for FY2025, 45.6% up from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was -$5.3 million at Akebia Therapeutics, up from -$6.4 million in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was -$5.3 million in Q4 2025, with the low at -$32.6 million in Q1 2022.
  • Average Other Gross PP&E Adjustments over 5 years is -$18.4 million, with a median of -$16.5 million recorded in 2023.
  • The sharpest move saw Other Gross PP&E Adjustments tumbled 30.81% in 2022, then soared 55.78% in 2023.
  • Over 5 years, Other Gross PP&E Adjustments stood at -$28.6 million in 2021, then grew by 19.86% to -$22.9 million in 2022, then increased by 18.93% to -$18.6 million in 2023, then skyrocketed by 48.01% to -$9.7 million in 2024, then skyrocketed by 45.6% to -$5.3 million in 2025.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at -$5.3 million, -$6.4 million, and -$7.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.